Wenbin Lu

Company: Daiichi Sankyo

Job title: Head of Clinical Development, Daiichi Sankyo China

Seminars:

Dato-DXd: Translating Mechanism of Action into Clinical Benefit for Patients with Breast & Lung Cancer 9:00 am

Overview of Dato-DXd mechanism of action and the DXd ADC platform Dato-DXd in breast cancer: TB01 registrational dataset and overview of the pivotal trial program in TNBC Dato-DXd in NSCLC: Efficacy/safety of Dato-DXd in EGFRm NSCLC supporting filing and overview of the pivotal trial program in NSCLCRead more

day: Scientific Program Day One AM